13F reference period
Q2 2026
Security Snapshot
TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK) Institutional Ownership
CUSIP: 874060205
13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026
Institutions Reporting
380
Shares (Excl. Options)
104.24M
Full value: 104,237,426 · shares · 30 Jun 2026Price
$16.03
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / SPONSORED ADS
- Symbol
- TAK on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 104,237,426
- Total 13F value
- $1,671,172,827
- Portfolio coverage rank
- 0%
- Share change
- +5,712,716
- Value change
- +$87,405,064
- Number of holders
- 380
- SEC-reported price per share
- $18.52
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
1 identity field
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- TAK - TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS is tracked under CUSIP 874060205.
- 380 institutions reported positions in Q2 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 362 to 380 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$1.82B
Full value: $1,818,794,858 · USD · 31 Mar 2026.$1.67B
Full value: $1,671,172,827 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 380 institutions filings for Q2 2026.
Security key
874060205
13F reference period
Q2 2026
13F holders
380
13D/G owners
0
CIK / CUSIP context first
Open Q2 2026 holders
TAK full holder history
TAKEDA PHARMACEUTICAL CO LTD SEC filings
TAKEDA PHARMACEUTICAL CO LTD company facts
TAKEDA PHARMACEUTICAL CO LTD insider transactions
TAKEDA PHARMACEUTICAL CO LTD 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 874060205:
As of 30 Jun 2026,
380
institutional investors reported holding
shares of
TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK).
104.24M
Full value: 104,237,426 · shares · 30 Jun 2026Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
51
Headline period
Q2 2026
Rows shown
1-25 of 51
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 3,704,290 | $67,424,081 | +$11,804,864 | $18.19 | 120 |
| 2026 Q2 | 104,237,426 | $1,671,172,827 | +$87,405,064 | $16.03 | 380 |
| 2026 Q1 | 98,241,470 | $1,818,794,858 | +$279,865,541 | $18.52 | 362 |
| 2025 Q4 | 83,746,535 | $1,305,638,001 | -$26,106,900 | $15.59 | 347 |
| 2025 Q3 | 85,210,658 | $1,247,493,378 | +$106,067,914 | $14.64 | 324 |
| 2025 Q2 | 77,806,509 | $1,202,785,823 | +$106,862,917 | $15.46 | 307 |
| 2025 Q1 | 71,086,493 | $1,057,034,943 | -$156,054 | $14.87 | 300 |
| 2024 Q4 | 72,039,413 | $953,847,647 | -$55,374,045 | $13.24 | 295 |
| 2024 Q3 | 71,553,169 | $1,015,380,211 | +$20,521,956 | $14.22 | 295 |
| 2024 Q2 | 72,061,993 | $940,730,985 | -$86,515,519 | $12.94 | 281 |
| 2024 Q1 | 78,179,293 | $1,087,229,460 | -$73,198,839 | $13.89 | 310 |
| 2023 Q4 | 83,396,860 | $1,190,086,769 | +$34,664,126 | $14.27 | 302 |
| 2023 Q3 | 80,437,115 | $1,242,500,598 | -$66,352,882 | $15.47 | 310 |
| 2023 Q2 | 84,017,983 | $1,320,003,579 | -$935,677 | $15.71 | 308 |
| 2023 Q1 | 82,262,152 | $1,355,589,943 | +$248,962,456 | $16.48 | 296 |
| 2022 Q4 | 68,069,757 | $1,063,701,562 | +$48,470,698 | $15.60 | 278 |
| 2022 Q3 | 63,905,792 | $829,049,514 | +$90,138,783 | $12.97 | 258 |
| 2022 Q2 | 56,978,507 | $799,748,914 | +$66,260,391 | $14.04 | 258 |
| 2022 Q1 | 56,159,628 | $802,855,152 | -$261,335,589 | $14.32 | 265 |
| 2021 Q4 | 75,991,152 | $1,037,422,048 | -$299,110,798 | $13.63 | 271 |
| 2021 Q3 | 91,971,894 | $1,505,006,212 | -$51,986,093 | $16.38 | 274 |
| 2021 Q2 | 94,938,677 | $1,598,252,322 | -$223,745,245 | $16.83 | 287 |
| 2021 Q1 | 107,728,479 | $1,962,038,029 | -$1,144,218 | $18.26 | 300 |
| 2020 Q4 | 108,743,491 | $1,978,272,193 | +$47,411,066 | $18.20 | 291 |
| 2020 Q3 | 107,411,892 | $1,906,842,183 | -$74,858,671 | $17.84 | 296 |